Skip to main content

Capricor Therapeutics, Inc.

CAPR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001133869

No open-market purchases or sales by Capricor Therapeutics, Inc. insiders were filed in the last 90 days; 169 institutions reported holding it in 13F filings for Q2 2026, worth $941.6M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding Capricor Therapeutics, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of CAPR: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders3130−1
Shares3.53M2.49M−1.04M (−29.4%)
Value$18.1M$10.0M−$8.07M (−44.6%)

New holders (6)

Institutions that held Capricor Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to CAPR in Q3 2021
InstitutionSharesValue% of portfolio
Virtu Financial LLC55,200$222.0K0.02%
Dimensional Fund Advisors LP28,621$115.0K0.00%
Goldman Sachs Group Inc22,138$89.0K0.00%
Two Sigma Securities, LLC11,511$46.0K0.01%
Advisor Group Holdings, Inc.5,000$20.0K0.00%
Total Clarity Wealth Management, Inc.75$00.00%

Sold out (7)

Institutions that held Capricor Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of CAPR in Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
Oracle Investment Management Inc1,166,249$5.98M
Susquehanna Fundamental Investments, LLC16,500$85.0K
Millennium Management LLC13,544$69.0K
UBS Group AG1,922$10.0K
Royal Bank of Canada1,387$7.00K
Deutsche Bank AG145$1.00K
JPMorgan Chase & Co77$0